INTERNATIONAL SUMMIT
ON PSYCHEDELIC THERAPIES FOR MENTAL ILLNESS

MELBOURNE AUSTRALIA // PARTNERSHIP PROPOSAL

17 - 20 NOVEMBER 2021 (2 Day Pre-Summit Introductory Workshop in Psychedelic Therapies + 2 Day Public Summit)
JOIN US

Mind Medicine Australia will hold a two-day International Summit on Psychedelic Therapies for Mental Illness in November 2021 in Melbourne, bringing together clinicians, scientists, academics, mental and public health professionals, philanthropists, Government, law and policy makers, business, industry, investors, consumers and other interested stakeholders.

The event will also feature a two-day pre-Summit introductory workshop program (17-18 November) for anyone with an interest in the topic and who is considering further development of their current therapeutic skills or who are eager to gain a detailed understanding of psychedelic-assisted psychotherapy for the treatment of mental illness.

The Summit will feature a rich program with a mixture of international and national keynotes, workshops, hot spots, panel conversations and gala dinner with Q & A.

Leading international speakers confirmed for the 2-day summit and Mind Medicine Australia Ambassadors include: Head of Neuropsychopharmacology at Imperial College London Prof David Nutt (UK), Executive Director of MAPS Dr Rick Doblin (USA), psychiatrist, researcher and writer Dr Ben Sessa (UK), Head of the Centre for Psychedelic Research at Imperial College London Dr Robin Carhart-Harris (UK), James B. Duke Professor of Psychology and Behavioural Economics at Duke University, Prof Dan Ariely (USA/Israel), Anthropologist, ethnobotanist and Explorer in Residence at the National Geographic Society Dr Wade Davis (Canada), Chairman and CEO of Eleusis Shlomi Raz (USA), leading Psychotherapist and Founder of the UK TRIPP Network Maria Papaspyrou (UK), Clinical Psychologist who was part of the team working on psilocybin trials at Imperial College, Renee Harvey (UK), Associate Director of the Center for Psychedelic and Consciousness Research at Johns Hopkins University School of Medicine, Prof Matthew Johnson (USA), Founder & Executive Director Neuroscape Adam Gazzaley M.D, PHD (USA), Clinical Psychologist, Research Scientist and Author Dr Adele Lafrance (USA), Psychedelic Psychiatrist & Researcher Dr Reid Robison (USA), Director of the University of Auckland’s Health Psychology Practitioner Programme Dr Lisa Reynolds (NZ), Deputy Secretary, Health Products Regulation Group - TGA John Skerritt and more TBA

Key themes will include:

- Ethical, legal, and implementation frameworks for psychedelic treatments
- The current state of mental health in Australia and existing treatments
- Clinical outcomes of psychedelic treatment for mental illness
- Therapeutic mechanisms of psychedelic treatments
- Enhancing effectiveness and minimising risks for psychedelic treatment
- The way forwards for Australia: Challenges and preparation towards creating a new paradigm

Psychedelic therapies have been granted Breakthrough Therapy status by the FDA in the USA due to current promising research in the treatment of depression and PTSD. We look forward to collaborating with you to explore psychedelic treatment options to help address the mental health crisis we currently face, and offer treatments to those who need it most.

We are delighted to extend an invitation to you and your colleagues to gather in Melbourne on 17-20 November 2021.

Together we can change the paradigm for mental health.

Venues: Sofitel Melbourne On Collins – The Summit
Workshop location TBC for Introductory Workshop in Psychedelic Therapies 2-day Workshop
ABOUT US

MEDICINE-ASSISTED THERAPIES

- Medicine-assisted therapy typically involves psychotherapy alongside the ingestion of a classical psychedelic such as psilocybin, or the compound MDMA.
- Over 100 current psychedelic trials active or recently completed globally
- Phase 1 and 2 clinical psychedelic trial results have been remarkable in terms of the strength, speed, and enduring outcomes of the treatment effect
- Strongest evidence to date: MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD); and psilocybin-assisted psychotherapy for depression, anxiety, and addiction
- Only 2-3 dosed sessions, with a few psychotherapy sessions before and after, has a lasting impact in 60-80% of patients (contrast conventional treatments: involves daily medication or weekly psychotherapy over long-term)
- Due to compelling results and urgent need, FDA has designated medicinal psilocybin and MDMA with ‘breakthrough therapy’ status (fast-tracked)
- Phase 3 trials are underway: positive results will lead to schedule change and prescription regulation

MIND MEDICINE AUSTRALIA

Mind Medicine Australia is a non-profit organisation seeking to develop safe and effective medicine-assisted treatments for mental illness in Australia. Mind Medicine Australia operates as a nexus between medical practitioners, academia, government, regulatory bodies, philanthropists, and other partners.

We work to educate and engage key stakeholders and the general public on clinical psychedelic research findings, develop therapist workshop programs and protocols, work with regulators towards appropriate policy, support clinical research, and prepare the way for possible service provision subject to adequate evidence and regulatory change.

We are ethical, responsible, and reliable. We stay close to the data, and openly discuss the benefits and risks. We hold the common good above commercial gain and are not profit-motivated.

We advocate only for the development of evidence-based and regulation-approved medicine-assisted treatments. Our work is wholly clinical; our purpose is to reduce mental ill-health in Australia.
# PROGRAM AT A GLANCE

Introductory Workshop in Psychedelic Therapies:
Wednesday 17th November & Thursday 18th November

## DAY 1: WEDNESDAY 17TH NOVEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:45-9:30am</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>9:30-10:30am</td>
<td>International Keynote</td>
</tr>
<tr>
<td>10:30-11am</td>
<td>Morning Tea</td>
</tr>
<tr>
<td>11-12:30pm</td>
<td>Plenary Session (3-4 presenters of 15 mins each plus Q &amp; A and Moderator)</td>
</tr>
<tr>
<td>12:30-1:30pm</td>
<td>Lunch</td>
</tr>
<tr>
<td>1:30-2:10pm</td>
<td>HOT SPOT circle sessions</td>
</tr>
<tr>
<td>2:15-3pm</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>3-3:45pm</td>
<td>International Keynote</td>
</tr>
<tr>
<td>3:45-4:30pm</td>
<td>Leaders Action Steps Panel (moderated)</td>
</tr>
<tr>
<td>4:30-5pm</td>
<td>Afternoon Tea</td>
</tr>
<tr>
<td>6:30 for 7pm</td>
<td>Gala Dinner with International Keynote, Q&amp;A and Entertainment</td>
</tr>
</tbody>
</table>

## DAY 2: THURSDAY 18TH NOVEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9-9:45am</td>
<td>International Keynote</td>
</tr>
<tr>
<td>9:45-10:30am</td>
<td>Keynote</td>
</tr>
<tr>
<td>10:30-11am</td>
<td>Morning Tea</td>
</tr>
<tr>
<td>11-12:30pm</td>
<td>Plenary Session (3-4 presenters of 15 mins each plus Q &amp; A and Moderator)</td>
</tr>
<tr>
<td>12:30-1:30pm</td>
<td>Lunch</td>
</tr>
<tr>
<td>1:30-2:10pm</td>
<td>HOT SPOT circle sessions</td>
</tr>
<tr>
<td>2:15-3pm</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>3-3:45pm</td>
<td>International Keynote</td>
</tr>
<tr>
<td>3:45-4:30pm</td>
<td>Leaders Action Steps Final Panel (moderated)</td>
</tr>
<tr>
<td>4:30-5pm</td>
<td>Afternoon Tea celebration with presenters and delegates</td>
</tr>
</tbody>
</table>

* Subject to change
SPEAKERS LINE-UP

Don’t miss the world class line-up of international researchers and leaders, alongside Mind Medicine Australia Ambassadors that are gathering at the summit to help us create a new paradigm in mental health.

PROFESSOR DAVID NUTT (UK)
Head of Neuropsychopharmacology at Imperial College London

DR RICK DOBLIN (USA)
Executive Director of MAPS (Multidisciplinary Association for Psychedelic Studies)

DR BEN SESSA (UK)
Psychoanalyst, Researcher and Writer

PROFESSOR DAN ARIELY (USA/ISRAEL)
James B. Duke Professor of Psychology and Behavioural Economics at Duke University

DR ADELE LAFRANCE (USA)
Clinical Psychologist, Research Scientist and Author

DR ROBIN CARHART-HARRIS (UK)
Head of the Centre for Psychedelic Research at Imperial College London

DR LISA REYNOLDS (NZ)
Health Psychologist and Director of the University of Auckland’s Health Psychology Practitioner Programme

REID ROBINSON, MD MBA (USA)
Psychiatrist with training in Neurodevelopmental Genetics & Clinical Research

WADE DAVIS CM (CANADA)
Professor of Anthropology & BC Leadership Chair in Cultures and Ecosystems at Risk at the University of British Columbia

PROFESSOR MATTHEW JOHNSON (USA)
Associate Director at the Johns Hopkins Center for Psychedelic & Consciousness Research

SHLOMI RAZ (USA)
Chairman and CEO of Elatea

PROFESSOR DAVID CASTLE
Chair of Psychiatry, St Vincent’s Health & The University of Melbourne

MARIAPAPASYROU (UK)
Psychotherapist and Writer, Founder TRIPP Network UK

DR SIMON LONGSTAFF AO
Executive Director of The Ethics Centre

RENEE HARVEY (UK)
Clinical Psychologist, Honorary Research Fellow at Imperial College London

ADAM GAZZALEY M.D. PHD (USA)
Founder & Executive Director at Neuroscape

PROF JOHN SKERRITT
Deputy Secretary, Health Products Regulation Group (TGA)

PETER HUNT AM
Investment Banker & Engaged Philanthropist; Founder Women’s Community Shelters and Mind Medicine Australia

TANIA DE JONG AM
Founder Creative Universe, Creativity Australia, Creative Innovation Global and Mind Medicine Australia

+ MANY MORE!
INTRODUCTORY WORKSHOP IN PSYCHEDELIC THERAPIES

(17 AND 18 NOVEMBER)

This Introductory Workshop for Psychedelic Therapies will run over two days prior to the International Summit on Psychedelic Therapies for Mental Illness. This will be a first-of-its-kind opportunity in Australia for those wanting to gain direct insight and training into this approach from international therapists in the field.

This workshop will be facilitated by leading Psychotherapist and Founder of the UK TRIPP Network Maria Papaspyrou (UK) and Clinical Psychologist for the psilocybin trials at Imperial College, Renee Harvey (UK).

The workshop will introduce participants to various approaches in psychedelic treatment for mental illness. This workshop is open to anyone with an interest in the topic and who is considering further development of their current therapeutic skills. It is particularly for those who are aiming to work in this field as and when these therapies become legally available in Australia.

It will cover an introductory background history to psychedelic medicines, how they work and how they are applied in research and clinical settings. There will be a significant practical component focussing on integration of experiences – how to understand and use the kinds of experience commonly encountered when using these substances for better selfunderstanding and how trained therapists might help someone apply them in their own lives.

The workshop will also provide a taster for the contents of the longer Professional Development Program for clinicians and trained therapists. These workshops are an opportunity to ‘test the waters’ for those interested in training up as certified medicine-assisted therapists. When this treatment receives regulatory approval in Australia, there will be demand for clinicians trained in the safe and effective provision of medicine-assisted therapy.

Medicine-assisted therapy is not yet legal in Australia, outside of a research context. However, given the impressive early clinical evidence to date, and the near-term regulatory changes predicted in the US and EU subject to forthcoming data, these workshops will contribute to preparing the Australia context for regulatory changes in the coming years.

The workshops will cover all three phases of medicine-assisted therapy: preparation, medicine session, and integration. Workshops will incorporate the theoretical neuroscience, psychology, psychotherapy), practical (instruction in methods of service provision), and experiential elements of treatment (process learning that deepens and develops clinicians’ capacity).
LEVERAGE YOUR PARTNERSHIP

The Mind Medicine International Summit will provide your organisation with a unique opportunity to be profiled as a leading innovator through partnering with this world class event. Your organisation will receive a host of benefits to enable engagement, conversation, and education for your leaders, emerging talent and stakeholders.

The program will give a limited number of organisations a range of benefits, including an opportunity to leverage the promotional campaign in the lead up to the Mind Medicine Australia 2021 International Summit, offer preferential and complimentary tickets, access to key speakers, and special Summit activities.

Benefits will include:

1. Identification as a Partner for the Mind Medicine Australia 2021 International Summit. This is a prestigious, high level national and international event for leaders and other decision makers.

2. Profiling in the program (at various levels) and the communications and website of Mind Medicine Australia.

3. The opportunity to educate and engage your staff, leaders and emerging talent individually or through sending teams via rewards/scholarships. Build new capabilities, enhance innovative thinking, and prepare for a new paradigm in mental health treatment.

4. Engagement of key stakeholders by offering VIP guest passes to the Mind Medicine Australia 2021 Summit.

5. Profile your organisation within email, social media, and press communications in the lead up to and during the Mind Medicine Australia 2021 Summit.

6. Access to papers and articles by our global presenters for your newsletters, magazines and journals, ongoing education, social media and web e-news.

7. Access to key Australian-based leaders who will be available for presentations, luncheons, seminars, workshops and events leading up to the event.

8. Opportunities to engage international speakers for presentations at luncheons, dinners, seminars, workshops and events around the Mind Medicine Australia International Summit 2021 event period.

9. Opportunities for your organisation to present interactive conversation circles ('Hot Spots') on topics to suit key themes, providing a great discussion forum.

10. Opportunities to share White Papers, thought leadership and relevant Announcements in the lead-up and during the event.

11. We are open to your creative thoughts to further leverage this event for a range of mutual benefits.

PARTNER INVESTMENT NOTES

• We are also developing in-kind and supplier partnerships for accommodation and travel for presenters, delegate satchels, technical production, media, etc.

• Education partnerships will be available for a range of like-minded membership and NFP and charitable organisations and will offer branding opportunities and discounted delegate places to your stakeholders in exchange for promotion of the event.
## PARTNERSHIP PACKAGES

<table>
<thead>
<tr>
<th>PARTNERSHIP BENEFITS</th>
<th>Leadership</th>
<th>Innovation</th>
<th>Foundation</th>
<th>Supporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platinum Delegate Tickets</td>
<td>25</td>
<td>12</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>Gala Event dinner incl. in platinum package</td>
<td>25 VIP tickets</td>
<td>12 VIP tickets</td>
<td>6 VIP tickets</td>
<td>3 VIP tickets</td>
</tr>
<tr>
<td>Professional Development Therapist Workshop</td>
<td>10 VIP tickets</td>
<td>5 VIP tickets</td>
<td>3 VIP tickets</td>
<td>2 VIP tickets</td>
</tr>
<tr>
<td>VIP Speakers Dinner</td>
<td>2 VIP Tickets for one of your senior leaders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VIP Function Opportunity</td>
<td>Private event for you and guests with a keynote speaker</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Logo/Brand</td>
<td>All material incl. marketing, web &amp; supporting materials.</td>
<td>Marketing material &amp; web</td>
<td>Marketing material &amp; web</td>
<td>Marketing material &amp; web</td>
</tr>
<tr>
<td>Signage</td>
<td>Quadruple size</td>
<td>Single size</td>
<td>Single size</td>
<td>Half size</td>
</tr>
<tr>
<td>Hot Spot Speaker</td>
<td>2 spots</td>
<td>1 spot</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Satchel Gifts innovative gifts from your organisation</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>1 YEAR INVESTMENT FEE (excluding GST)</td>
<td>$50,000</td>
<td>$25,000</td>
<td>$17,500</td>
<td>$10,000</td>
</tr>
</tbody>
</table>
DISPLAY OPPORTUNITY

Mind Medicine Australia have an exciting opportunity for your business or organisation to host a display. An exclusive display will provide maximum brand exposure/awareness and face to face interaction with conference delegates, speakers and VIPs.

The venue allows for 10 display areas, so please be quick to confirm your space.

Cost = $3,450 + GST including:

• A display table with 2 chairs and space for your materials and banners
• A complimentary ticket to the 2 day Summit
• Mind Medicine Australia will include your organisation and company logo in the Summit program and on the website.
A very special opportunity to join one of our international leaders at the gala event dinner! For a $5000 donation to Mind Medicine Australia, you will receive:

- Places for your 10 guests
- An international leader seated at the table

There are limited VIP tables available so get in early!
WHO WILL ATTEND?

Attendees will include medical, scientific, research, allied health, legal, Government, philanthropic, business, investment and other industry leaders and emerging talent.

Delegates are expected to comprise of 40% Victorian, 30% Interstate and 30% International. Attendees will include leaders, professionals, clinicians, academics and emerging talent from these fields:

- Medicine
- Psychiatry
- Psychology
- General Practice
- Psychotherapy
- Mental Health
- Science
- Research and Academia
- Allied Health
- Agribusiness and Manufacturing
- Investors and Business Leaders
- Law, Human Rights and Ethics
- Government and Public Policy
- Philanthropy
- Arts and Culture
- Consumers
- Other interested stakeholders

Demographics by location:

- 40% Victoria
- 30% Interstate
- 30% International
“...My hope is that we will engage in mature, evidence-based discussions about how best to fund and deploy psychedelic-assisted psychotherapies to augment existing approaches to the treatment of mental illness. I hope that governments will have the courage to put the welfare of their citizens ahead of their fear of controversy – and that our politicians will deploy their considerable skills and positions of influence to nurture a balanced and objective understanding amongst the public.” Dr Simon Longstaff AO, Leading Australian Ethicist and Executive Director of The Ethics Centre

“I would like to see psychedelics … re-established as medicine... it’s so important that we tell the truth about these drugs, because if we don’t, we are losing an enormous amount of therapeutic potential. This is potentially a revolution in the treatment of depression and could arguably be the greatest contribution to health since the vaccine.” Professor David Nutt, Head of Neuropsychopharmacology, Imperial College London

“...Psychedelics have been plagued by an incomplete and often inaccurate understanding of their risks and benefits. Extensive research since the 1950s, and in particular over the last two decades, shows that when done responsibly, psychedelic-assisted therapy and/or interventions are safe for humans and effective for the treatment of certain mental illnesses, including anxiety disorders, substance use disorders, and depression.” Dr Rick Doblin, Director of MAPS

“There continues to be substantial untreated morbidity for many people with mental health problems; we urgently need to explore new treatment paradigms, and the promise of psychedelic medicines in terms of alleviation of suffering cannot be under-estimated.” Professor David Castle, Psychiatrist at St Vincent’s Hospital and the University of Melbourne

“Early stage clinical research has shown that when delivered safely and professionally, psychedelic therapy holds great promise for treating some very serious mental health conditions.” Dr Robin Carhart-Harris, Head of the Imperial Centre for Psychedelic Research, Imperial College London

“Australia currently lags behind the international research and development community (Johns Hopkins, Imperial College London, Harvard, Stanford) in understanding the role that psychedelic medicine might play in the treatment of mental illness. A growing evidence base regarding psychedelic medicine and the importance of providing choice to consumers to access ‘the right care at the right time’ warrants careful consideration of the role that psychedelic medicine might play in supporting holistic mental healthcare in Australia.” Professor Jane Burns, Professor of Social Innovation, Swinburne University
It does not seem to be an exaggeration to say that psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology and medicine.”

Dr Stanislav Grof

Mental ill-health is estimated to cost the Australian economy almost $60 billion per year.

MARKETING, MEDIA & PR
We will be working with all of our Partners to maximise the benefits of the event. There is significant and growing interest in the subject matter, and strong media coverage for Mind Medicine Australia since its launch. Please visit our NEWS page to see recent media coverage.

We expect enormous interest throughout all media including TV, radio, online and print.

DIGITAL ASSETS
Following the event, we will produce a high quality digital assets and video library of all presentations at the event.

In addition to the event speakers, other presentations will be published under the Mind Medicine Australia brand, and will provide a rich library of Australian and global thought leadership and education. These assets will offer an ongoing interactive resource for Partner organisations to leverage. The assets will be distributed through online hubs, the event website, and event partner education and professional development programs.

POSTERS, SCHOLARSHIPS AND YOUNG LEADERS
Submissions are invited for poster presentations that represent original and new, important or relevant science, research, technology, clinical application or public health related to medicine-assisted therapies.

We will offer at least 10 scholarships to emerging scientific leaders and researchers through a competitive national application process, providing the opportunity to attend the event, deliver presentations, and meet key speakers and delegates.

Both poster and scholarship applicants will also be eligible to apply as a Young Leader. Young Leaders are applicants of 35 years of age or under who are currently involved in research, a related project or have an incredible idea that will contribute to the field of psychedelic medicine in an innovative or integral way. Successful Young Leaders will be invited to form the inaugural membership of a new committee within Mind Medicine Australia for 2021.
AMBASSADORS
Dr Rick Doblin (USA)
Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS).

Professor David Nutt (UK)
Head of Neuropsychopharmacology at Imperial College London

Professor Roland Griffiths Ph.D
Professor of Psychiatry and Behavioural Sciences at Johns Hopkins School of Medicine

Dr Ben Sessa MD (UK)
Psychiatrist, Researcher & Writer

BOARD OF DIRECTORS
Peter Hunt AM
Co-founder Mind Medicine Australia, Investment Banker & Engaged Philanthropist; Founder, Women’s Community Shelters

Tania de Jong AM
Co-founder Mind Medicine Australia, Founder, Creative Universe; Creativity Australia & Creative Innovation Global

Admiral Chris Barrie AC
Founder and Chair, PTSD-Australia New Zealand; Former Chief of the Australian Defense Force.

Professor Jane Burns
Chair of Open Arms, Chair of STREAT and Chair of the Centre for Mental Health, Swinburne University

Dr Simon Longstaff AO
Director, the Ethics Centre

Mono Ray
CEO & Founder, ConnectAlex; Non-Executive Director, Kidney Health Australia

The Hon Andrew Robb AO
Australia’s Minister for Trade and Investment (2013-2016); Chair of Asia Link

Nicholas Smedley
Managing Director, Steller

ADVISORY PANEL
Dr Tanveer Ahmed
Psychiatrist and Author

Dr Mahsheed Ansari
Centre for Islamic Studies and Civilisation (CISAC) Charles Sturt University

Greg Barns
Barrister

Prof James Bennett-Levy
Professor of Mental Health and Psychological Wellbeing, University of Sydney

Prof Michael Berk
NHMRC Senior Principal Research Fellow

Prof Ashley Bush
NHMRC Senior Principal Research Fellow, Director of the Melbourne Dementia Research Centre

Dr David Caldicott
Adjunct Professor, University of Canberra & Emergency Consultant

Dr Robin Carhart-Harris (UK)
Founder, Centre for Psychedelic Research at Imperial College London

Dr Ted Cassidy
Psychiatrist and Co-Founder of TMS Australia

Dr Mark Cross
Psychiatrist

Dr Wade Davis CM (Canada)
Anthropologist and writer

Dr James Fadiman (USA)
Psychologist and Author

Amanda Feilding (UK)
Founder and Executive Director of the Beckley Foundation

Prof Paul Fitzgerald
Professor of Psychiatry at Monash University and Director of the Epworth Centre for Innovation in Mental Health

Prof David Forbes
Psychologist

Prof Paul Frijters (UK)
Research Fellow London School of Economics

Prof Gregg Henriques (USA)
Clinical Psychologist

Dr Karen Hitchcock
General Physician

Prof Malcolm Hopwood
Ramsay Health Care Professor of Psychiatry, University of Melbourne

Tommy Huppert
Founder and CEO of Cannatrek Limited

Prof Matthew W. Johnson (USA)
Associate Director at Johns Hopkins School of Medicine

Linda Kader
Psychiatrist and Senior Lecturer at the Department of Psychiatry, University of Melbourne

Rabbi Zac Kamenetz
Educator, Rabbi and aspiring Healer

Michael Kornhauser
Pharmaceutical and Clinical Trial Research Specialist

Dr Eli Kotler
Psychiatrist and Director of Medicine at Malvern Private Hospital
AMBASSADORS, BOARD, ADVISORY PANEL & TEAM

Dr Adele Lafrance (USA)
Clinical Psychologist, Research Scientist and Author

Prof. Andrew Lawrence
NHMRC Principal Research Fellow & Division Head at the
Florey Institute of Neuroscience & Mental Health

Scott Leckie
Human Rights Lawyer, Professor at Monash University and
Found of Displacement Solutions

Rev Graham Long AM
Pastor Emeritus, The Wayside Chapel, Sydney

Dr Paul MacLeman
Corporate Advisor

Dennis McKenna (USA)
Ethnopharmacologist, Author, Founder Heffter Research
Institute

Rob Moodie AM
Professor of Public Health, University of Melbourne and
Adviser to WHO

Dr David E. Nichols (USA)
Adjunct Professor of Chemical Biology and Medicinal
Chemistry, University of North Carolina, Chapel Hill

Sean O’Carroll
Private Practice Psychotherapist

Dr Nikola Ognyenovits
Addiction Medicine Specialist Physician

Dr Thomas Pogge (USA)
Philosopher & Director of the Global Justice Program at Yale

Nigel Pollard
Medicine Business Specialist

Dr Prash Puspanathan
Neuropsychiatry Fellow, Alfred Hospital, Melbourne

Dr Jamie Rickcord
Founder Ananda Clinics

Dr Reid Robison (USA)
Psychedelic Psychiatrist & Researcher

Dr Arne Rubinstein
Founder & CEO, The Rites of Passage Institute

Dr James Rucker (UK)
Consultant Psychiatrist & Senior Clinical Lecturer

Prof Avni Sali AM
Founding Director of NIIM, and Member of the Scientific
Board of The European Congress for Integrative Medicine

Dr Patrycja Slawuta (USA)
NYC-based Researcher and Entrepreneur. Founder,
SelfHackathon

Imam Tawidi
Islamic Scholar, Educator, Author and Global Speaker

Prof John Tiller
Professor Emeritus of Psychiatry, University of Melbourne

Dr Jeremy Weate
CEO of Universal Ibogaine

Dr John Webber
Psychiatrist

Dr Alex Wodak AM
Physician; Director of Australia 21 and President, the
Australian Drug Law Reform Foundation

Rabbi Dr Laibl Wolf
Dean and Founder of the Spiritgrow Wellness Centre,
Melbourne Australia

TEAM

Tania de Jong AM
Executive Director

Renee Harvey
Manager of Psychedelic Therapy Development Program

Dr Alana Roy
Practice Manager

Ilan Hayman
Operations Manager

Julia Neubauer
Digital Communications, Design and Social Media Consultant

Melissa Warner
Education and Communications Fellow

Erin Whelan
Administration and Events Officer

Thomas Velican
Volunteers, Grants and Chapter Coordinator
NEXT STEPS FOR A NEW PARADIGM IN MENTAL HEALTH

Please contact us for your chance to be involved:

Tania de Jong AM, Co-Founder and Executive Director, Mind Medicine Australia
P +61 (03) 8679 6015 € tania@mindmedicineaustralia.org

Ilan Hayman, Operations Manager, Mind Medicine Australia
€ ilan@mindmedicineaustralia.org